Abstract
Measurement of high sensitivity CRP (hsCRP) and lipoprotein-associated phospholipase A2 (LpPLA2) provides information on systemic inflammation and stability of atherosclerotic plaques. Data analyzing the effect of smoking on these parameters are sparse. The aim of our study was the analysis of these parameters in active smokers and never-smokers. The study included 777 smokers and 1,178 never-smokers, of whom 221 and 302 died during a follow-up, respectively. The values of LpPLA2 and hsCRP were significantly higher in smokers than in never-smokers. Mortality was highest in smokers and never-smokers with elevation of both biomarkers. Multivariate adjusted hazard ratios for patients in the highest tertile of both hsCRP and LpPLA2 compared with patients in the lowest tertile of both markers were 1.85 (1.04–3.28) in never-smokers and 1.94 (1.10–3.45) in smokers. Our data confirmed the predictive value of hsCRP and LpPLA2. However, there were a relevant number of patients with an increase of only one of these parameters. Therefore, beside other risk factors for cardiovascular disease, both parameters should be determined at least in high risk patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR (2004) Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 109:837–842
Barua RS, Ambrose JA (2013) Mechanisms of coronary thrombosis in cigarette smoke exposure. Thromb Vasc Biol 33:1460–1467
Corson MA, Jones PH, Davidson MH (2008) Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 101:41F–50F
Craig WY, Palomaki GE, Haddow JE (1989) Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ 298:784–788
Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJL, Ezzati M (2009) The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle and metabolic risk factors. PLoS Med 6:e1000058
Fröhlich M, Sund M, Löwel H, Imhof A, Hoffmeister A, Koenig W (2003) Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J 24:1365–1372
Genser B, Grammer TB, Stojakovic T, Siekmeier R, März W (2008) Effect of HMG CoA reductase inhibitors on low-density lipoprotein cholesterol and C-reactive protein: systematic review and meta-analysis. Int J Clin Pharmacol Ther 46:497–510
Hastie CE, Haw S, Pell JP (2008) Impact of smoking cessation and lifetime exposure on C-reactive protein. Nicotine Tob Res 10:637–642
Kleber ME, Wolfert RL, De Moissl GD, Grammer TB, Dietz S, Winkelmann BR, Boehm BO, März W (2011) Lipoprotein associated phospholipase A2 concentration predicts total and cardiovascular mortality independently of established risk factors (The Ludwigshafen Risk and Cardiovascular Health Study). Clin Lab 57:659–667
Lavi S, Prasad A, Yang EH, Mathew V, Simari RD, Rihal CS, Lerman LO, Lerman A (2007) Smoking is associated with epicardial coronary endothelial dysfunction and elevated white blood cell count in patients with chest pain and early coronary artery disease. Circulation 115:2621–2627
Libby P (2002) Inflammation in atherosclerosis. Nature 420:868–874
Mao J, Liu J, Pang X, Li M, Song J, Han C, Wu D, Wang S (2012) Nicotine indices the expression of C-reactive protein via MAPK-dependent signal pathway in U937 macrophages. Mol Cells 34:457–461
National Cholesterol Education Program Expert Panel on Detection E, treatment of high blood cholesterol in A: third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421, 2002
Packard CJ, O’Reilly DSJ, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GDO, The West of Scotland Coronary Prevention Study Group (2000) Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med 343:1148–1155
Price JF, Mowbray PI, Lee AJ, Rumley A, Lowe GDO, Fowkes FGR (1999) Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease. Eur Heart J 20:344–353
Ridker PM (2003) Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107:363–369
Ridker PM (2009) C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. Clin Chem 55:209–215
Ross R (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340:115–126
Stafforini DM (2009) Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther 23:73–83
Sudhir K (2005) Clinical review: lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J Clin Endocrinol Metab 90:3100–3105
Tselepis AD, Panagiotakos DB, Pitsavos C, Tellis CC, Chrysohoou C, Stefanadis C (2009) Smoking induces lipoprotein-associated phospholipase A2 in cardiovascular disease free adults: the ATTICA Study. Atherosclerosis 206:303–308
U.S. Department of Health and Human Services (2006) The health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon General. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA, pp 1–710
Wallner-Liebmann SJ, Grammer TB, Siekmeier R, Mangge H, März W, Renner W (2013) Smoking denial in cardiovascular disease studies. Adv Exp Med Biol 788:35–38
Wannamethee SG, Lowe GDO, Shape AG, Rumley A, Lennon L, Whincup PH (2005) Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J 26:1765–1773
Winkelmann BR, März W, Boehm BO, Zotz R, Hager J, Hellstern P, Senges J (2001) Rationale and design of the LURIC study – a resource for functional genomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2(Suppl 1):S1–S73
Yanbaeva D, Dentener MA, Creutzberg EC, Wesseling G, Wouters EFM (2007) Systemic effects of smoking. Chest 131:1557–1566
Acknowledgements
We extend our appreciation to the participants of the LURIC study. We thank the LURIC study team who were either temporarily or permanently involved in patient recruitment as well as sample and data handling, in addition to the laboratory staff at the Ludwigshafen General Hospital and the Universities of Freiburg and Ulm, Germany. LURIC has received funding from the 6th Framework Program (integrated project Bloodomics, grant LSHM-CT-2004-503485) and from the 7th Framework Program (Atheroremo, grant agreement number 201668 and RiskyCAD, grant agreement number 305739) of the European Union.
Conflicts of Interest
The authors declare no conflicts of interest in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Kleber, M.E. et al. (2014). C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Smokers and Nonsmokers of the Ludwigshafen Risk and Cardiovascular Health Study. In: Pokorski, M. (eds) Oxidative Stress and Cardiorespiratory Function. Advances in Experimental Medicine and Biology(), vol 832. Springer, Cham. https://doi.org/10.1007/5584_2014_6
Download citation
DOI: https://doi.org/10.1007/5584_2014_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-09721-3
Online ISBN: 978-3-319-09722-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)